Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Doxorubicin; Lenalidomide; Vinblastine

Criteria

Inclusion Criteria:

• Hodgkin Lymphoma, intermediate or advanced stage

• Age >60 and <75 years

• ECOG 2 or better

• No major organ dysfunction

• Ability to take aspirin or LMW Heparin

Exclusion Criteria:

• HL as composite lymphoma

• Prior use of lenalidomide

• Prior use of chemo- or radiotherapy